COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc > AEZS's Macimorelin and PGX

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jul 11, 2024 8:26am

86 Views

Post# 36127893

RE:AEZS's Macimorelin and PGX

We've never heard the company say anything about it and I don't know if there is anything to it. It could be Ai hallucinations but this is what an Ai program is saying...

--

Integrating Ceapro's PGX technology with macimorelin could potentially improve the oral bioavailability and absorption of macimorelin in several ways:

Increasing the solubility of macimorelin, which has limited solubility in water (300 mg/mL). PGX technology uses supercritical fluid extraction and impregnation to produce highly soluble, amorphous drug formulations.
Enhancing permeability across the intestinal membrane by modifying the physicochemical properties of macimorelin. PGX can produce drug-polymer solid dispersions that improve permeability.
Reducing first-pass metabolism of macimorelin by CYP3A4. PGX can encapsulate drugs in biopolymer matrices that protect against metabolism.
Enabling more precise dosing by producing a standardized, homogeneous macimorelin formulation with consistent bioavailability. This could optimize the diagnostic accuracy compared to the current oral solution.
Potentially allowing the test to be administered at home rather than in a clinical setting, if the improved formulation provides sufficient stability and absorption consistency.

However, more research would be needed to determine if PGX can provide meaningful improvements in macimorelin's already good oral bioavailability (45 minutes to peak concentrations). The current 0.5 mg/kg dose already shows high accuracy in diagnosing adult growth hormone deficiency.